Eikon COO granted 87,157 stock options

Eikon Therapeutics, Inc. reported that Chief Operating Officer Michael A. Klobuchar received a grant of stock options for 87,157 shares at an exercise price of $0.00 per share.

Accepted by SEC EDGAR 03/04/2026 - 05:04 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Eikon Therapeutics, Inc. reported that Chief Operating Officer Michael A. Klobuchar received a grant of stock options for 87,157 shares at an exercise price of $0.00 per share. The award vests in equal monthly installments over 48 months, subject to his continued service.

Insider Trade Summary

Grant/Award: 87,157 shares

Grant/Award 1 txn

Insider Klobuchar Michael A

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	87,157	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 87,157 contracts (Direct)

Holdings Before and After: Stock Option (Right to Buy), 0 to 87,157 contracts (Direct)

Footnotes (1)

1. F1. 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did EIKN report for Michael A. Klobuchar?

Eikon Therapeutics reported a stock option grant to Chief Operating Officer Michael A. Klobuchar covering 87,157 shares. This was reported as an acquisition under a grant or award, rather than an open-market purchase or sale of common stock.

How many Eikon Therapeutics (EIKN) options were granted in this Form 4?

The Form 4 shows a grant of stock options covering 87,157 shares of Eikon Therapeutics common stock. These options were reported with an exercise price of $0.00 per share and are held directly by Michael A. Klobuchar as the reporting person.

What is the vesting schedule for the EIKN stock options granted to the COO?

The options vest monthly over four years. Specifically, 1/48th of the 87,157 underlying shares vests on each monthly anniversary of the vesting start date for 48 months, conditioned on Michael A. Klobuchar’s continued service through each vesting date.

Was the EIKN transaction a purchase or sale of common stock?

The transaction was not an open-market purchase or sale of common stock. It is reported as a grant or award acquisition of stock options, giving Michael A. Klobuchar the right to buy 87,157 shares in the future subject to vesting terms.

What role does Michael A. Klobuchar hold at Eikon Therapeutics (EIKN)?

Michael A. Klobuchar is identified as an officer of Eikon Therapeutics, serving as Chief Operating Officer. The Form 4 attributes the 87,157-share stock option grant directly to him in this executive capacity, subject to the stated vesting schedule and ownership terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Klobuchar Michael A

(Last) (First) (Middle)

C/O EIKON THERAPEUTICS, INC.

230 HARRIET TUBMAN WAY

(Street)

MILLBRAE CA 94030

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Eikon Therapeutics, Inc. [ EIKN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$14.88	03/02/2026		A		87,157		(1)	03/01/2036	Common Stock	87,157	$0	87,157	D

Explanation of Responses:

1. 1/48th of the shares underlying the option will vest on each monthly anniversary of the vesting start date for 48 months, subject to the Reporting Person's continued service through each date.

	/s/ Benjamin Thorner, Attorney-in-Fact	03/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.